Author

K. Van Moer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Chevigne· 1 shared B. Janji· 1 shared G. Berchem· 1 shared M. Ollert· 1 shared M. Szpakowska· 1 shared M. Xiao· 1 shared M. Z. Noman· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chevigne

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma

M. Z. Noman, M. Szpakowska, M. Xiao, K. Van Moer, M. Ollert, G. Berchem, A. Chevigne, B. Janji

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.

bioRxiv · Apr 2, 2024 · PreprintCancer Biology